LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
22 funds hold it · 7 straight earnings beats
No insider open-market trades in 90 days (SEC Form 4). Congress: net buying of $17K to $80K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 22, 2026
Period ending
Sep 30, 2026
Earnings per share
-$27.83 expected
Revenue
Financial statements: Alpha Vantage
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 22, 2026 | $7.80est. -$27.83 | +128.03%beat | EUR 1.72BAlpha Vantage | No year-ago quarter |
| Jun 30, 2026Reported Jul 23, 2026 | $7.32est. $6.19 | +18.17%beat | EUR 2.82BAlpha Vantage | +197.0%from EUR 948.0M |
| Mar 31, 2026Reported May 7, 2026 | $5.52est. $4.92 | +12.12%beat | $1.30BAlpha Vantage | No year-ago quarter |
| Dec 31, 2025Reported Feb 26, 2026 | $8.02est. $6.11 | +31.24%beat | EUR 3.21BAlpha Vantage | +138.1%from EUR 1.35B |
| Sep 30, 2025Reported Oct 30, 2025 | $5.18est. $4.16 | +24.52%beat | $1.13BAlpha Vantage | No year-ago quarter |
| Jun 30, 2025Reported Jul 31, 2025 | $3.74est. $3.02 | +23.84%beat | EUR 948.0MAlpha Vantage | +65.4%from EUR 573.2M |
| Mar 31, 2025Reported May 8, 2025 | $2.58est. $2.31 | +11.69%beat | EUR 790.7MAlpha Vantage | +97.2%from EUR 401.0M |
| Dec 31, 2024Reported Mar 31, 2025 | $0.71est. $1.70 | -58.04%miss | EUR 1.35BAlpha Vantage | +235.7%from EUR 401.0M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Sep 2025 | Mar 2026 |
|---|---|---|
| What came in | ||
| Revenue | $1.13B | $1.30B |
| Cost of what it sold | $109.0M | $121.0M |
| Gross profit | $1.02B | $1.18B |
| What it spent | ||
| Research and development | $359.0M | $443.0M |
| Sales and admin | $336.0M | $355.0M |
| Other operating costs | $85.0M | $106.0M |
| Total operating expenses | $780.0M | $904.0M |
| What was left | ||
| Operating profit | $347.0M | $394.0M |
| Interest on debt | $1.0M | $1.0M |
| Profit before tax | $386.0M | $426.0M |
| Net profit | $344.0M | $366.0M |
| EBITDA | $387.0M | $427.0M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
argenx stock advances as peptide deal broadens drug discovery
BullishNov 10argenx stock targets oral therapies with $1.15 billion deal
BullishNov 10If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today
BullishNov 9argenx stock lifts BEL 20 as peptide deal enters focus
BullishNov 9A new drug-discovery approach could help argenx pursue medicines taken by mouth for immune diseases.
BullishNov 9Argenx to Acquire Biotech Unnatural Products for Up to $1.15 Billion
BullishNov 9Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
BullishNov 9argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
BullishNov 736 macro signals shaping ARGX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
